Breaking News, Financial News

Financial Report: Merck 2Q

Worldwide sales of Singulair were $1.3 billion in the quarter (+ 16%). Combined sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $1.0 billion (-10%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck 2Q 2Q Revenues: $5.9 billion (-3%) 2Q Earnings: $1.6 billion (-12%) YTD revenues: $11.3 billion (-5%) YTD Earnings: $3.0 billion (-41%) Comments: Worldwide sales of Singulair were $1.3 billion in the quarter (+ 16%). Combined sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $1.0 billion (-10%). Cozaar and Hyzaar sales were $906 million (-4%). Gardasil sales were $268 million (-18%). Rotateq sales were $126 million (-29%). Januvia sales ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters